About Us | CHMR | University of Nebraska Medical Center

AML-M2

Missions:

Leverage a world-class clinical research center in hematological malignancies and increase extramural funding through innovative and collaborative research
Foster the academic growth of young professionals and train the next generation of oncologists, scientists and physician-scientists
Development of personalized medicine/targeted therapy for hematological malignancies through the Clinical Oncogenomics Proposal for the Buffett Cancer Center; and expanding the scope of clinical trials in hematological malignancies through clinical / translational research

What's In a Name?

The story behind our namesake.

Dr. Armitage started the lymphoma and stem cell transplant programs at UNMC in the early 1980’s. UNMC was one of the first transplant centers to pioneer the use of peripheral blood stem cells for use in the transplant which has now become the standard of care at all centers worldwide. Dr. Armitage was a major part of this early discovery and published many of the early lymphoma peripheral blood stem cell transplant studies. In addition, he has also been a major contributor to the research and literature evaluating the biology and classification of lymphomas as well as many of the early clinical trials with new agents for the treatment of lymphoma. These activities have put UNMC at the top of the list for institutions that specialize in lymphoma research.

Julie M. Vose, MD, MBA
Division Chief, Oncology & Hematology, UNMC